Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Dow, Eli Lilly
Prediction: This Will be Eli Lilly's Next Big Move.
This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped revenue to soar in the double digits -- and that's resulted in a surging share price too,
Eli Lilly & Co. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The stock has also outperformed the sector as well as the S&P 500 as seen in the chart below.
16h
Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
2d
Eli Lilly urges court to toss $183 mln Medicaid fraud judgment
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
10h
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
1d
Lilly Wants Records of People Who Took Weight-Loss Knockoffs
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...
16h
Eli Lilly’s Competitive Edge in Weight Loss Medication Market Bolstered by Orforglipron’s Promising Trial Results
Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...
Ibj.com
2d
Eli Lilly requests records of people who took copies of its weight-loss drug
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
USA Today
5d
New eczema drug from Eli Lilly receives FDA approval for children and adults
On Friday, the U.S. Food and Drug Administration approved
Eli
Lilly
's eczema drug for use in adults and children 12 and ...
7d
6 Incredible Reasons to Invest in Eli Lilly
Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...
3h
Little Support For Eli Lilly's High Valuation
An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Novo Nordisk
S&P 500 Index
New York Stock Exchange
Apple
United States
Feedback